AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31653518 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal phosphorus diet
Number of subjects: 8
Study 31653518 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude exposure
Number of subjects: 8
Study 31653518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and high-altitude exposure
Number of subjects: 8
Study 30014865 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavonoid cocoa drink (350 mg gallic acid equivalents {GAE}/g)
Number of subjects: 12
Study 30014865 — intervention group
Group type: COMPARATOR
Intervention: Low flavonoid cocoa control (120 mg GAE/g)
Number of subjects: 12
Study 26977123 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Skills Training (YST)
Number of subjects: 15
Study 26977123 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 15
Study 23571810 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐925 150 mg
Number of subjects: 117
Study 23571810 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐925 50 mg
Number of subjects: 117
Study 23571810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 20974485 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing the procedure on a video monitor (Group A)
Number of subjects: 76
Study 20974485 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 76
Study 18844328 — intervention group
Group type: EXPERIMENTAL
Intervention: Yamabushitake (Hericium erinaceus) - 250 mg tablets, 4 tablets three times a day for 16 weeks
Number of subjects: 30
Study 18844328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16429088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent patients with conduct disorder and substance use disorder
Number of subjects: 20
Study 16429088 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study 14970979 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) at 0 Hz
Number of subjects: 140
Study 14970979 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) at 5 Hz
Number of subjects: 140
Study 14970979 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) at 100 Hz
Number of subjects: 140
Study 14970979 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation (TENS) at 5 Hz
Number of subjects: 140
Study 14970979 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation (TENS) at 100 Hz
Number of subjects: 140
Study 14970979 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 140
Study 14970979 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation
Number of subjects: 140
Study 11741100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline, a long-acting dopamine agonist, dosage and duration not specified
Number of subjects: 0
Study 11741100 — intervention group
Group type: COMPARATOR
Intervention: Levodopa, a dopaminergic agent, dosage and duration not specified
Number of subjects: 0
Study 9682673 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose aprotinin (Group 2)
Number of subjects: 30
Study 9682673 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose aprotinin (Group 3)
Number of subjects: 30
Study 9682673 — intervention group
Group type: COMPARATOR
Intervention: Cytomix alone (control group)
Number of subjects: 30
Study 9682673 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (in vitro)
Number of subjects: 30
Study 8161288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluphenazine hydrochloride (5 mg twice daily)
Number of subjects: 80
Study 8161288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 2961624 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 88
Study 2961624 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 88
Study 2961624 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical elimination of endometriosis
Number of subjects: 88
Study 2961624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 29669963 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 171
Study 29669963 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 171
Study 29669963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Nicorandil
Number of subjects: 171
Study 27549626 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection-primed group (IP)
Number of subjects: 80
Study 27549626 — intervention group
Group type: COMPARATOR
Intervention: Vaccine-primed group (VP)
Number of subjects: 80
Study 25681720 — intervention group
Group type: EXPERIMENTAL
Intervention: ODTs containing core granules
Number of subjects: 0
Study 25681720 — intervention group
Group type: COMPARATOR
Intervention: ODTs containing placebo
Number of subjects: 0
Study 25681720 — intervention group
Group type: EXPERIMENTAL
Intervention: Core granules with particle sizes ≥ 200 μm
Number of subjects: 0
Study 25681720 — intervention group
Group type: EXPERIMENTAL
Intervention: ODTs with coated core granules
Number of subjects: 0
Study 25681720 — intervention group
Group type: EXPERIMENTAL
Intervention: Core granules composed of water-soluble additives
Number of subjects: 0
Study 25681720 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold particle size of core granule
Number of subjects: 0
Study 22592447 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm to self (HTS) counseling intervention
Number of subjects: 40
Study 22592447 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm to others (HTO) counseling intervention
Number of subjects: 40
Study 20588019 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning during primary angioplasty (PA) and stenting
Number of subjects: 78
Study 20588019 — intervention group
Group type: COMPARATOR
Intervention: Plain primary angioplasty (PA) without postconditioning
Number of subjects: 78
Study 20588019 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 78
Study 18371483 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statin therapy
Number of subjects: 4178
Study 18371483 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated GFR <60 mL/min
Number of subjects: 4178
Study 18371483 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP in the fourth quartile
Number of subjects: 4178
Study 16618300 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of tropisetron (0.1 mg x kg(‐1), max 2 mg) immediately after inhalational induction
Number of subjects: 120
Study 16618300 — intervention group
Group type: EXPERIMENTAL
Intervention: Late administration of tropisetron (0.1 mg x kg(‐1), max 2 mg) after the end of surgery before extubation
Number of subjects: 120
Study 16618300 — intervention group
Group type: EXPERIMENTAL
Intervention: Late administration of tropisetron
Number of subjects: 120
Study 16618300 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of tropisetron
Number of subjects: 120
Study 16618300 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and late administration of tropisetron
Number of subjects: 120
Study 12788301 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led heart failure clinic follow-up
Number of subjects: 106
Study 11007220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.i.d. for 30 days
Number of subjects: 60
Study 11007220 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.i.d. for 30 days
Number of subjects: 60
Study 11007220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 60
Study 11007220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8831847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysate from cultured allogeneic keratinocytes
Number of subjects: 50
Study 8831847 — intervention group
Group type: COMPARATOR
Intervention: Control group (antibiotic suspension only)
Number of subjects: 50
Study 8173689 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of felodipine plus metoprolol 5/50‐10/100 mg (FM)
Number of subjects: 58
Study 8173689 — intervention group
Group type: COMPARATOR
Intervention: Felodipine 5‐10 mg (F)
Number of subjects: 58
Study 8173689 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 50‐100 mg (M)
Number of subjects: 58
Study 3527886 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LH); n = 29
Number of subjects: 56
Study 3527886 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UH); n = 27
Number of subjects: 56
Study 29654053 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride and fluoride varnish
Number of subjects: 0
Study 29654053 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish and glass ionomer therapeutic sealants
Number of subjects: 0
Study 27189681 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate (25 mg/kg, intravenous, single dose)
Number of subjects: 90
Study 27189681 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (single dose)
Number of subjects: 90
Study 24059690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 138
Study 24059690 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily (titrated to 100 mg for non-responders)
Number of subjects: 138
Study 23420326 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication group (group M) treated with pioglitazone
Number of subjects: 24
Study 23420326 — intervention group
Group type: COMPARATOR
Intervention: Gallstone group (group G)
Number of subjects: 24
Study 23420326 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (group C)
Number of subjects: 24
Study 23420326 — intervention group
Group type: EXPERIMENTAL
Intervention: Human cholesterol gallstone patients
Number of subjects: 24
Study 23420326 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 19477733 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (walking on a treadmill for 60 min at 65% age‐predicted maximum heart rate)
Number of subjects: 80
Study 19477733 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 80
Study 18975365 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU every other day)
Number of subjects: 39144
Study 18975365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39144
Study 16324915 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride + 4 mg rosiglitazone
Number of subjects: 102
Study 16324915 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride + 8 mg rosiglitazone
Number of subjects: 102
Study 16324915 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride + placebo
Number of subjects: 102
Study 14653829 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) 2 x 320 mg plant extract t.d.s.
Number of subjects: 247
Study 14653829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 14653829 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE)
Number of subjects: 247
Study 10988190 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen (SuppO2)
Number of subjects: 51
Study 10988190 — intervention group
Group type: COMPARATOR
Intervention: Compressed Air (CA)
Number of subjects: 51
Study 8971428 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (loading dose 5 mg kg‐1 over 20 min, followed by 0.5 mg kg‐1 min‐1)
Number of subjects: 0
Study 8971428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.21 mg kg‐1 h‐1)
Number of subjects: 0
Study 8971428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 0
Study 1317691 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiorphan (2.5 mg/ml, 0.5 ml)
Number of subjects: 8
Study 1317691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6742538 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam (0.33 mg X kg‐1)
Number of subjects: 75
Study 6742538 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg X kg‐1)
Number of subjects: 75
Study 6742538 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.4 mg X kg‐1)
Number of subjects: 75
Study 30875090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Oxycodone
Number of subjects: 100
Study 30875090 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Sufentanil
Number of subjects: 100
Study 29052102 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro Emotional Technique (NET) intervention
Number of subjects: 0
Study 29052102 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 27741166 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve B632 and BR03; 5 drops of active product (10 viable cells/strain) for 90 days
Number of subjects: 23
Study 27741166 — intervention group
Group type: COMPARATOR
Intervention: Placebo; 5 drops of placebo for 90 days
Number of subjects: 23
Study 24780450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycaemic control (TGC): insulin by intravenous infusion titrated to maintain blood glucose between 4.0 and 7.0 mmol/l.
Number of subjects: 1369
Study 24780450 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (CM): insulin by intravenous infusion only if blood glucose exceeded 12.0 mmol/l on two samples at least 30 minutes apart; insulin was stopped when blood glucose fell below 10.0 mmol/l.
Number of subjects: 1369
Study 22855332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice a day)
Number of subjects: 28
Study 22855332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 20532723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 3 mg/kg/hr infusion)
Number of subjects: 90
Study 20532723 — intervention group
Group type: COMPARATOR
Intervention: Control (matching placebo)
Number of subjects: 90
Study 20532723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 90
Study 20532723 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 18782527 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine interventions
Number of subjects: 0
Study 18782527 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16255352 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement containing 2.5% chlorhexidine (GI-CHX)
Number of subjects: 262
Study 16255352 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer (GI)
Number of subjects: 262
Study 16255352 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 262
Study 12492906 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg CHX 2 x daily for 30 s (0.1% CHX)
Number of subjects: 20
Study 12492906 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg CHX 2 x daily for 60 s (0.06% CHX)
Number of subjects: 20
Study 12492906 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml SFAF rinse 1 x daily for 30 s
Number of subjects: 20
Study 12492906 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg CHX 2 x daily for 30 s (0.06% CHX)
Number of subjects: 20
Study 12492906 — intervention group
Group type: COMPARATOR
Intervention: 15 ml placebo 2 x daily for 60 s
Number of subjects: 20
Study 10030791 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinjury PMNs stimulated with LPS (100 ng)
Number of subjects: 12
Study 10030791 — intervention group
Group type: COMPARATOR
Intervention: Elective surgical patients (control)
Number of subjects: 12
Study 10030791 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinjury PMNs
Number of subjects: 12
Study 8525690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered at 0, 2, and 6 months of age
Number of subjects: 626
Study 8525690 — intervention group
Group type: COMPARATOR
Intervention: DTP and oral polio vaccines
Number of subjects: 626
Study 8525690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 626
Study 8525690 — intervention group
Group type: COMPARATOR
Intervention: DTP vaccine
Number of subjects: 626
Study 8525690 — intervention group
Group type: COMPARATOR
Intervention: Polio vaccine
Number of subjects: 626
Study 8525690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine with DTP and polio vaccines
Number of subjects: 626
Study 2359570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg three times daily during menses)
Number of subjects: 72
Study 2359570 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone (5 mg twice daily on days 19-26 of the cycle)
Number of subjects: 72
Study 1119429 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg albumen
Number of subjects: 0
Study 1119429 — intervention group
Group type: COMPARATOR
Intervention: Amino acid mixture (essential and nonessential)
Number of subjects: 0
Study 1119429 — intervention group
Group type: COMPARATOR
Intervention: Essential amino acids plus nonspecific nitrogen
Number of subjects: 0
Study 1119429 — intervention group
Group type: COMPARATOR
Intervention: Elemental diet
Number of subjects: 0
Study 1119429 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with egg albumen
Number of subjects: 0
Study 31764564 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscope-Assisted Coblation Adenoidectomy (EACA)
Number of subjects: 72
Study 31764564 — intervention group
Group type: COMPARATOR
Intervention: Conventional Curettage Adenoidectomy (CCA)
Number of subjects: 72
Study 30854750 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified one-handed chest compression (OHCC)
Number of subjects: 46
Study 30854750 — intervention group
Group type: COMPARATOR
Intervention: Conventional one-handed chest compression (OHCC)
Number of subjects: 46
Study 30854750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both modified and conventional OHCC
Number of subjects: 46
Study 27486204 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 250 mg daily for 8 weeks
Number of subjects: 20
Study 27486204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26527788 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy at 3 years and 6 years (group B)
Number of subjects: 528
Study 26527788 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy at 6 years (group A)
Number of subjects: 528
Study 24163386 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram plus placebo
Number of subjects: 662
Study 24163386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion plus escitalopram
Number of subjects: 662
Study 24163386 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine plus mirtazapine
Number of subjects: 662
Study 24163386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BMI
Number of subjects: 662
Study 21525260 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea polyphenols beverage providing 1402 mg total catechins/d
Number of subjects: 60
Study 21525260 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea polyphenols beverage
Number of subjects: 60
Study 21525260 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea polyphenols (0.5, 1.0, and 2.0 g) in a separate study
Number of subjects: 60
Study 21525260 — intervention group
Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 60
Study 19448047 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Audio Computer‐Assisted Self‐Interviewing (T‐ACASI)
Number of subjects: 2287
Study 16537867 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox inhalation for 1 hour
Number of subjects: 20
Study 16537867 — intervention group
Group type: COMPARATOR
Intervention: Airox inhalation for 1 hour
Number of subjects: 20
Study 12751807 — intervention group
Group type: EXPERIMENTAL
Intervention: Task A easy with Task B difficult
Number of subjects: 0
Study 12751807 — intervention group
Group type: EXPERIMENTAL
Intervention: Task A easy with Task B easy
Number of subjects: 0
Study 12751807 — intervention group
Group type: EXPERIMENTAL
Intervention: Task A difficult with Task B easy
Number of subjects: 0
Study 12751807 — intervention group
Group type: EXPERIMENTAL
Intervention: Task A difficult with Task B difficult
Number of subjects: 0
Study 10831074 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. mycophenolate mofetil (MMF) 1 g Q12h
Number of subjects: 198
Study 10831074 — intervention group
Group type: COMPARATOR
Intervention: Placebo (used in the safety study only, 2:1 MMF:placebo)
Number of subjects: 198
Study 10831074 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. mycophenolate mofetil (MMF) 1 g b.i.d.
Number of subjects: 198
Study 9085956 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (3 mg/kg)
Number of subjects: 40
Study 9085956 — intervention group
Group type: COMPARATOR
Intervention: 0.25% lidocaine (1.5 mg/kg) with 1 microg/kg of fentanyl and 0.5 mg of pancuronium
Number of subjects: 40
Study 8462137 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg daily)
Number of subjects: 64
Study 8462137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 3028660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide administered with mesna (IFO/M)
Number of subjects: 0
Study 30144512 — intervention group
Group type: COMPARATOR
Intervention: Weight gain subgroup (n=43)
Number of subjects: 347
Study 30144512 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable weight subgroup (n=260)
Number of subjects: 347
Study 27088583 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV‐13 booster
Number of subjects: 178
Study 27088583 — intervention group
Group type: COMPARATOR
Intervention: PCV‐10 booster
Number of subjects: 178
Study 25055491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2‐0.7 microg/kg per hour)
Number of subjects: 55
Study 25055491 — intervention group
Group type: COMPARATOR
Intervention: Propofol (0.3‐2 mg/kg per hour)
Number of subjects: 55
Study 22079736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy combined with long-term androgen deprivation therapy
Number of subjects: 97